RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 45.13M shares outstanding
USRenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies.
The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination.
It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
Kirsten Angela Macfarlane
Director
Laurence J. Marton, M.D.
Director
Leesa Gentry
Chief Clinical Officer
Mark Voll
CFO & Principal Accounting Officer
Employees
17
Country
US
Sector
Healthcare
Website
renovorx.com
Loading congressional disclosures…
based on 45.13M shares outstanding
US30d Avg
599.72K
60d Avg
1.05M
90d Avg
788.08K
